Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain 36C pseudogene (ENSG00000277878) is classified as a pseudogene, meaning it is a nonfunctional DNA segment that resembles a protein-coding gene—in this case, related to the ankyrin repeat domain family, whose true functional member is ANKRD36C[5]. Pseudogenes typically arise through genomic duplication or retrotransposition, but lose the ability to code for a functional protein due to accumulated disabling mutations such as frameshifts or premature stop codons[4][2]. There is no evidence that this pseudogene produces a functional RNA or protein, nor is it implicated as a therapeutic target or a biomarker. Pseudogenes like this may complicate genetic analysis but generally have no known biological function or disease relevance[4][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain 36C pseudogene (ANKRD36C-pseudogene).